NASDAQ:APRE
Aprea Therapeutics Inc. Stock News
$5.27
-0.320 (-5.72%)
At Close: May 17, 2024
APRE Stock: Why It Increased Today
09:30am, Monday, 20'th Sep 2021
The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) is trading higher today. This is why it happened.
Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts
10:25am, Sunday, 19'th Sep 2021
Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
04:15pm, Thursday, 12'th Aug 2021
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the
Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study
06:37am, Thursday, 12'th Aug 2021
After instituting a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) myeloid malignancies program, the FDA has placed a clinical hold on Aprea's lymphoid malignancy study. The
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
06:00am, Thursday, 12'th Aug 2021
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutan
Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials
08:14am, Friday, 06'th Aug 2021
The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) clinical trials of eprenetapopt (APR-246) combined with azacitidine in its myeloid malignancy programs.
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
05:00pm, Thursday, 05'th Aug 2021
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutan
Implied Volatility Surging for Aprea (APRE) Stock Options
09:47am, Friday, 18'th Jun 2021
Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
10:32am, Thursday, 17'th Jun 2021
Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.
STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase
Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded
03:49pm, Wednesday, 16'th Jun 2021
Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?
APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today
12:07pm, Wednesday, 16'th Jun 2021
Aprea Therapeutics (APRE) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial. The post APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics S
APRE Stock Price Increases Over 40%: Why It Happened
10:30am, Wednesday, 16'th Jun 2021
The stock price of Aprea Therapeutics, Inc. (NASDAQ: APRE) increased by over 40% during intraday trading this morning. This is why it happened.
Why Aprea Therapeutics Shares Are Surging Today
09:06am, Wednesday, 16'th Jun 2021
Aprea Therapeutics Inc (NASDAQ:APRE) shares are trading higher by 46% at $7.07 after the company announced the Phase 1/2 trial of eprenetapopt with venetoclax and azacitidine in TP53 mutant AML met th
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
06:00am, Friday, 21'st May 2021
BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant